MAP2K7 and colorectal carcinoma: SCH772984, a novel ERK inhibitor, effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistance models and reversed the sensitivity of including CRC to BRAF and MEK inhibitors [25].